CDNA (CareDx, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by CDNA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-06 | George Bickerstaff | Director | Sell | — | — |
| 2026-08-06 | Michael Goldberg | Director | Sell | — | — |
| 2026-08-06 | Jeffrey Adam Novack | Secretary and General Counsel | Sell | — | — |
| 2026-08-06 | CHRISTINE COURNOYER | Director | Sell | — | — |
| 2026-08-06 | Jeffrey Adam Novack | Secretary and General Counsel | Sell | — | — |
| 2026-08-06 | George Bickerstaff | Director | Sell | — | — |
| 2026-08-06 | Michael Goldberg | Director | Sell | — | — |
| 2026-08-06 | CHRISTINE COURNOYER | Director | Sell | — | — |
| 2026-08-04 | Jeffrey Adam Novack | Secretary and General Counsel | F | — | — |
| 2026-07-17 | John Walter Hanna JR | President and CEO | MIXED | — | — |
| 2026-07-17 | Hannah Valantine | Director | MIXED | — | — |
| 2026-07-07 | Michael Goldberg | Director | A | — | — |
| 2026-07-06 | John Walter Hanna JR | President and CEO | F | — | — |
| 2026-07-02 | Jeffrey Adam Novack | Secretary and General Counsel | F | — | — |
| 2026-07-02 | Keith Kennedy | CFO & COO | F | — | — |
| 2026-07-02 | Jessica Meng | Chief Commercial Officer | F | — | — |
| 2026-06-17 | John Walter Hanna JR | President and CEO | Sell | — | — |
| 2026-06-16 | Michael Goldberg | Director | A | — | — |
| 2026-06-16 | Suresh Gunasekaran | Director | A | — | — |
| 2026-06-16 | Hannah Valantine | Director | MIXED | — | — |
| 2026-06-16 | George Bickerstaff | Director | A | — | — |
| 2026-06-16 | Fred E Cohen | Director | A | — | — |
| 2026-06-16 | Richard Bryan Riggsbee | Director | A | — | — |
| 2026-06-16 | CHRISTINE COURNOYER | Director | A | — | — |
| 2026-06-15 | John Walter Hanna JR | President and CEO | Sell | — | — |
| 2026-06-09 | Jeffrey Adam Novack | Secretary and General Counsel | F | — | — |
| 2026-06-08 | John Walter Hanna JR | President and CEO | Sell | — | — |
| 2026-05-18 | ARTHUR A TORRES | Director | Sell | — | — |
| 2026-05-06 | Jeffrey Adam Novack | Secretary and General Counsel | Sell | — | — |
| 2026-05-04 | Jeffrey Adam Novack | Secretary and General Counsel | F | — | — |
| 2026-04-22 | Keith Kennedy | CFO & COO | A | — | — |
| 2026-04-20 | John Walter Hanna JR | President and CEO | Sell | — | — |
| 2026-04-16 | John Walter Hanna JR | President and CEO | F | — | — |
| 2026-04-07 | Jeffrey Adam Novack | Secretary and General Counsel | F | — | — |
| 2026-04-03 | Jeffrey Adam Novack | Secretary and General Counsel | F | — | — |
| 2026-04-03 | Michael Goldberg | Director | A | — | — |
| 2026-04-03 | Jessica Meng | Chief Commercial Officer | F | — | — |
| 2026-04-03 | Keith Kennedy | CFO & COO | F | — | — |
| 2026-04-03 | John Walter Hanna JR | President and CEO | F | — | — |
| 2026-04-01 | Michael Goldberg | Director | M | — | — |
| 2026-02-04 | John Walter Hanna JR | President and CEO | MIXED | — | — |
| 2026-02-04 | Jeffrey Adam Novack | Secretary and General Counsel | MIXED | — | — |
| 2026-02-04 | Keith Kennedy | Chief Operating Officer | MIXED | — | — |
| 2026-02-04 | Jessica Meng | Chief Commercial Officer | MIXED | — | — |
| 2026-02-04 | NATHAN SMITH | Chief Financial Officer | MIXED | — | — |
| 2026-01-23 | John Walter Hanna JR | President and CEO | Sell | — | — |
| 2026-01-20 | John Walter Hanna JR | President and CEO | Sell | — | — |
| 2026-01-07 | Michael Goldberg | Director | A | — | — |
| 2025-12-05 | Jeffrey Adam Novack | Secretary and General Counsel | Sell | — | — |
| 2025-11-10 | Jeffrey Adam Novack | Secretary and General Counsel | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 1,032,252 | — |
| — | 10%+ Owner | 960,090 | — |
| — | Director | 773,086 | — |
| — | President and CEO | 721,448 | — |
| — | See Remarks | 515,986 | — |
| — | See Remarks | 479,164 | — |
| — | 10%+ Owner | 431,270 | — |
| — | Chief Financial Officer | 319,725 | — |
| — | Director | 309,846 | — |
| — | See Remarks | 284,983 | — |
| — | CFO & COO | 219,924 | — |
| — | Chief Commercial Officer | 168,287 | — |
| — | Director | 165,060 | — |
| — | Director | 152,783 | — |
| — | Director | 134,061 | — |
| — | Chief Financial Officer | 126,277 | — |
| — | Secretary and General Counsel | 106,575 | — |
| — | Chief Operating Officer | 96,559 | — |
| — | Chief Marketing Officer | 78,420 | — |
| — | Chief Financial Officer | 75,000 | — |
| — | Director | 73,370 | — |
| — | Chief Medical Officer | 62,045 | — |
| — | Director | 58,177 | — |
| — | Chief Financial Officer | 50,000 | — |
| — | Director | 44,292 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CDNA quote page; the site-wide leaderboard is on the insider transactions hub.